

8

 참고 문헌

1. 노영석, 서대현, 유동수, 이성열, 심우영, 이원수, 이동윤 & 박현정. 피부과학. 대한의학. 2014
2. Andrade RJ, Lucena MI, Fernandez MC, Suarez F, Montero JL, Fraga E, et al. Fulminant liver failure associated with flutamide therapy for hirsutism. *Lancet* 1999;353:983.
3. Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary syndrome. *Best Pract Res Clin Obstet Gynaecol* 2004;18:737-54.
4. Azziz R. The time has come to simplify the evaluation of the hirsute patient. *Fertil Steril* 2000;74:870-2.
5. Azziz R. The evaluation and management of hirsutism. *Obstet Gynecol* 2003;101:995-1007.
6. Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. *Endocr Rev* 2000;21:347-62.
7. Barrionuevo P, Nabhan M, Altayar O, et al. Treatment options for hirsutism: a systematic review and network meta-analysis. *J Clin Endocrinol Metab* 2018;103:1258-64.
8. Batukan C, Muderris II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. *Fertil Steril* 2006;85:436-40.
9. Brodell LA, Mercurio MG. Hirsutism: Diagnosis and management. *Gend Med* 2010;7:79-87.
10. Buzney E, Sheu J, Buzney C, Reynolds RV. Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment. *J Am Acad Dermatol*. 2014;71:859.e1-859.e15;quiz 873-4.
11. Carmina E, Rosato F, Janni A, et al. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. *J Clin Endocrinol Metab* 2006;91:2-6.
12. Cheewadhanaraks S, Peeyananjarassri K, Choksuchat C. Clinical diagnosis of hirsutism in Thai women. *J Med Assoc Thai* 2004;87:459-63.
13. Cotterill JA, Cunliffe WJ. Suicide in dermatological patients. *Br J Dermatol* 1997;137:246-50.
14. Conway GS, Honour JW, Jacobs HS. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. *Clin Endocrinol (Oxf)* 1989;30:459-70.
15. Cosma M, Swiglo BA, Flynn DN, Kurtz DM, Labella ML, Mullan RJ, et al. Clinical review: Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. *J Clin Endocrinol Metab* 2000;93:1135-42.
16. Darney PD. The androgenicity of progestins. *Am J Med* 1995;98:104S-110S.
17. Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. *Endocr Rev* 2000;21:363-92.
18. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. *Endocr Rev* 1995;16:322-53.
19. Falsetti L, Gambera A, Andrico S, Sartori E. Acne and hirsutism in polycystic ovary syndrome: clinical, endocrine-metabolic and ultrasonographic differences. *Gynecol Endocrinol* 2002;16:275-84.
20. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. *J Clin Endocrinol Metab* 1961;21:1440-7.
21. Fraison E, Kostova E, Moran LJ, Bilal S, Ee CC, Venetis C, et al. Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome. *Cochrane Database Syst Rev*. 2020;8:CD005552.
22. Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. *J Clin Endocrinol Metab* 2004;89:2817-

- 23.
23. Haedersdal M, Gotzsche PC. Laser and photoepilation for unwanted hair growth. *Cochrane Database Syst Rev* 2006;18:CD004684.
24. Haseltine F. Androgens and women's health: a National Institute of Child Health and Human Development Conference: The Holiday Inn Crowne Plaza, Rockville, Maryland, March 29-30, 1994, Belle Mead, NJ: Reed Elsevier Medical Publication; 1994.
25. Hamzavi I, Tan E, Shapiro J, Lui H. A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women. *J Am Acad Dermatol* 2007;57:54-9.
26. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. *Am J Obstet Gynecol* 1981;140:815-30.
27. Housman E, Reynolds RV. Polycystic ovary syndrome: a review for dermatologists: Part I. Diagnosis and manifestations. *J Am Acad Dermatol*. 2014;71:847.e1-847.e10;quiz 857-8.
28. Kaplan B. Desogestrel, norgestimate, and gestodene: the newer progestins. *Ann Pharmacother* 1995;29:736-42.
29. Kim JJ, Chae SJ, Choi YM, Hwang SS, Hwang KR, Kim SM, et al. Assessment of hirsutism among Korean women: results of a randomly selected sample of women seeking pre-employment physical check-up. *Hum Reprod* 2011;26:214-20.
30. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. *J Clin Endocrinol Metab* 1998;83:3078-82.
31. Koulouri O, Conway GS. A systematic review of commonly used medical treatments for hirsutism in women. *Clin Endocrinol (Oxf)* 2008;68:800-5.
32. Koulouri O, Conway GS. Management of hirsutism. *BMJ* 2009;338:b847.
33. Kriplani A, Periyasamy AJ, Agarwal N, Kulshrestha V, Kumar A, Ammini AC. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. *Contraception* 2010;82:139-46.
34. Mackenzie IS, Macdonald TM, Thompson A, Morant S, Wei L. Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. *BMJ* 2012;345:e4447.
35. Martin KA, Anderson RR, Chang RJ, Ehrmann DA, Lobo RA, Murad MH, et al. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 2018;103:1233-57.
36. Mastorakos G, Koliopoulos K, Creasas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. *Fertil Steril* 2002;77:919-27.
37. Mofid A, Seyyed Alinaghi SA, Zandieh S, Yazdani T. Hirsutism. *Int J Clin Pract* 2008;62:433-43.
38. Olsen EA. Methods of hair removal. *J Am Acad Dermatol* 1999;40:143-55;quiz 56-7.
39. Orfanos CE, Adler YD, Zouboulis CC. The SAHA syndrome. *Horm Res* 2000;54:251-8.
40. Palep-Singh M, Mook K, Barth J, Balen A. An observational study of Yasmin in the management of women with polycystic ovary syndrome. *J Fam Plann Reprod Health Care* 2004;30:163-5.
41. Randall VA. Androgens and hair growth. *Dermatol Ther* 2008;21:314-28.
42. Shapiro J, Lui H. Vaniqa--eflornithine 13.9% cream. *Skin Therapy Lett* 2001;6:1-3, 5.
43. Shaw JC, White LE. Long-term safety of spironolactone in acne: results of an 8-year followup study. *J Cutan Med Surg* 2002;6:541-5.
44. Somani N, Harrison S, Bergfeld WF. The clinical evaluation of hirsutism. *Dermatol Ther* 2008;21:376-91.
45. Taylor HS, Pal L, Seli E. Speroff's clinical gynecologic endocrinology and infertility. 9th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2020
46. Thiboutot D, Chen W. Update and future of hormonal therapy in acne. *Dermatology* 2003;206:57-67.
47. Van Zuuren EJ, Fedorowicz Z, Carter B, Pandis N. Interventions for hirsutism (excluding laser and photoepilation therapy alone). *Cochrane Database Syst Rev* 2015;(4):CD010334.
48. Waggoner W, Boots LR, Azziz R. Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms: a populational study. *Gynecol Endocrinol* 1999;13:394-400.
49. Wolf JE Jr, Shander D, Huber F, Jackson J, Lin CS, Mathes BM, et al. Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair. *Int J Dermatol* 2007;46:94-8.
50. Wijeyaratne CN, Balen AH, Barth JH, et al. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? *Clin Endocrinol (Oxf)* 2002;57:343-50.
51. Zawar V, Sankalecha C. Facial hirsutism following danazol therapy. *Cutis* 2004;74:301-3.